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Abstract. Adrenomedullin (ADM) is a regulatory peptide 
endowed with multiple biological effects, including the regula-
tion of blood pressure, cell growth and innate host defence. In 
the present study, we demonstrated that ADM signaling could 
be involved in the impaired cellular differentiation of myeloid 
leukemia cells to mature granulocytes or monocytes by modu-
lating RAMPs/CRLR expression, PI3K/Akt cascade and the 
ERK/MAPK signaling pathway. When exogenously admin-
istered to in vitro cultures of HL60 promyelocytic leukemia 
cells, ADM was shown to exert a strong proliferative effect 
with minimal upregulation in the expression level of monocyte 
antigen CD14. Notably, the experimental inhibition of ADM 
signaling with inhibitor ADM22-52 promoted a differentiative 
stimulation towards monocytic and granulocytic lineages. 
Moreover, based on the expression of CD31 relative to CD38, 
we hypothesized that an excess of ADM in bone marrow 
(BM) niche could increase the transendothelial migration of 
leukemia cells while any inhibitory event of ADM activity 
could raise cell retention in hyaluronate matrix by upregu-
lating CD38. Taken into consideration the above evidence, we 
concluded that ADM and ADM22-52 could differently affect the 
growth of leukemia cells by autocrine/paracrine mechanisms 
and may have clinical relevance as biological targets for the 
intervention of tumor progression.
Introduction
Acute myeloid leukemias are a heterogeneous group of clonal 
neoplastic diseases due to genetic and epigenetic alterations 
of hematopoietic stem cells (HSCs) or committed progenitors, 
causing an aberrant growth of myeloid precursor cells. 
Acute promyelocytic leukemia (APL), a subtype of AML, 
is characterized by an abnormal accumulation of promyelo-
cytes following specific translocation t(15;17) (q21;12) and 
formation of promyelocytic leukemia (PML)/retinoic acid 
receptor α (RARα) fusion gene. It has been demonstrated that 
the PML-RARα fusion protein is involved in the pathogenesis 
of APL through the recruitment of a complex that, composed 
of nuclear co-repressor molecule (NCOR) and histone deacety-
lase (HDAC), inhibits the expression of myeloid differentiation 
genes (1). Under treatment with all-trans-retinoic acid (ATRA), 
the NCOR/HDAC complex is dissociated from RAR and the 
maturation of promyelocytes is restored. Standard protocols 
combining ATRA with anthracycline-based chemotherapy are 
demonstrated to guarantee ~70% cure rate (2).
Originally isolated from human pheochromocytoma, 
adrenomedullin is a 52 aa peptide belonging to the calcitonin 
gene-related peptide family (3). Its maturation involves the 
proteolytic cleavage of preproadrenomedullin, a precursor of 
185 amino acid residues that includes at amino terminal end the 
so-called proadrenomedullin N-terminal 20 peptide (PAMP), 
a peptide with known transient hypotensive activity (4,5).
The biological effects of ADM are mainly mediated by 
its interaction with two cell-surface receptors, multimeric 
complexes of calcitonin receptor-like receptor (CRLR) and 
receptor-activity-modifying proteins (RAMPs). It is known 
that the RAMP family includes three members (RAMP1, 
RAMP2 and RAMP3) and regulates both transport and ligand 
specificity of CRLR. When RAMP2 or RAMP3 is associ-
ated with CRLR, adrenomedullin receptors 1 (AMR1) and 2 
(AMR2) are generated, respectively, while RAMP1 is included 
in calcitonin gene-related peptide (CGRP) receptors (6,7).
Although ADM was first described as a potent vasodilator 
and hypotensive factor, several studies reported that it exerts 
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various biological activities acting in an autocrine/paracrine 
manner (8). ADM is produced and secreted by several cell 
types, such as neurons, epithelial and endothelial cells 
supporting their survival and/or proliferation (9). Compelling 
evidence has shown that adrenomedullin can contribute to the 
pathogenesis of solid tumors in several ways (10). Firstly, the 
hypoxic conditions induce an upregulation of the peptide in the 
tumor cells leading to stimulation of cell growth and inhibition 
of apoptosis (11). Secondly, ADM exerts proangiogenic effects 
thus providing nutrients and oxygen to the tumor and allowing 
the spreading of tumor cells (12). Thirdly, it decreases the 
expression of proinflammatory cytokines, thus, inhibiting the 
immune system (13).
ADM is involved in the regulation of hematopoietic 
compartment as demonstrated by its expression in periph-
eral blood granulocytes, lymphocytes, monocytes and 
monocyte-derived macrophages under homeostatic and 
lipopolysaccharide-induced inflammation (14-16). Notably, 
ADM stimulates the proliferation of human cord blood hema-
topoietic stem cells through autocrine mechanism (17,18).
Based on the above evidence and considering that ADM 
plays a critical role in cancer cell proliferation, the aim of 
the present study was to evaluate whether ADM signaling is 
involved in the maintenance of impaired differentiation of 
APL cells to mature granulocytes or monocytes. Thus, the 
proliferative and differentiative effects induced by ADM and 
its inhibitor, ADM22-52, were evaluated in vitro at different 
time-points in HL60 cells, a human promyelocytic leukaemia 
cell line widely used to study granulocyte differentiation (19).
Materials and methods
Cell culture. Human promyelocytic leukaemia cell line HL60 
(kindly provided by CRO, Aviano, Italy) was grown in Iscove's 
medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented 
with 10% fetal bovine serum (FBS; Sigma-Aldrich) and 1% 
antibiotic antimycotic solution (Sigma-Aldrich) at 37˚C in a 
humidified atmosphere containing 5% CO2.
Flow cytometry (FCM). The expression level of endogenous 
ADM (ADMendo), RAMP1, RAMP2, RAMP3 and CRLR 
was studied in HL60 cells cultured under resting or primed 
conditions with exogenous ADM (ADMexo) and ADM22-52. 
After washing with 0.5% BSA in PBS, the samples were 
Table I. Antibodies used for flow cytometric analysis.
Antibodies Manufacturing company
Primary antibodies
  FITC rat anti-human CD11b BD Biosciences
  FITC mouse anti-human CD11c BD Biosciences
  PE mouse anti-human CD14 Santa Cruz Biotecnology
  PE mouse anti-human CD31 Dako
  FITC mouse anti-human CD33 BD Biosciences
  FITC mouse anti-human CD34 BD Biosciences
  Mouse anti-human CD38 Santa Cruz Biotecnology
  PE mouse anti-human CD45 Santa Cruz Biotecnology
  PE mouse anti-human cKIT Santa Cruz Biotecnology
  PE mouse anti-human HLA DR Santa Cruz Biotecnology
  FITC mouse anti-human Lineage cocktail 1 (CD3, CD14, CD16, CD19, CD20, CD56) BD Biosciences
  Goat anti-human ADM Santa Cruz Biotecnology
  Rabbit anti-human RAMP1 Santa Cruz Biotecnology
  Rabbit anti-human RAMP2 Santa Cruz Biotecnology
  Rabbit anti-human RAMP3 Santa Cruz Biotecnology
  Goat anti-human CRLR Santa Cruz Biotecnology
  Rabbit anti-human Akt Santa Cruz Biotecnology
  Rabbit anti-human p(Ser473)-Akt Santa Cruz Biotecnology
  Rabbit anti-human p44/42 MAPK Cell Signaling Technology
  Rabbit anti-human phosho (Thr202/Tyr204)-p44/42 MAPK Cell Signaling Technology
Secondary antibodies
  PE goat anti-mouse Santa Cruz Biotecnology
  PE donkey anti-goat  Santa Cruz Biotecnology
  Alexa Fluor 488 goat anti-rabbit  Invitrogen-Life Technologies
Isotype controls
  PE isotype control Santa Cruz Biotecnology
  FITC isotype control BD Biosciences
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incubated with primary antibodies (Table I) for 15 min at 
room temperature (RT). For indirect staining, the detection of 
specific binding sites was carried out by staining for 15 min 
at RT with Alexa Fluor® 488- or PE-conjugated secondary 
antibodies. For intracellular staining, HL60 cells were pre-
fixed with BD Cytofix/Cytoperm solution (BD Biosciences, 
San Josè, CA, USA) for 20 min at 4˚C. Data were analyzed by 
FACSCanto II flow cytometer (BD Biosciences) and expressed 
as percentage (%) ± standard deviation (SD) of positive cells 
compared with II antibody (Ab)- or isotype-matched controls. 
Statistical significance was calculated by Student's t-test.
Gene expression study of PAM. Total mRNA of HL60 cells 
was isolated using TRIzol® reagent (Sigma-Aldrich), according 
to the manufacturer's protocol. From each sample, 1 µg total 
RNA was reverse transcribed into cDNA by using M-MLv 
reverse transcriptase (Sigma-Aldrich), and oligo (dT)23 
primers (Invitrogen-Life Technologies, Paisley, UK). The 
amplification reaction was performed by PTC-100 thermal 
cycler (Bio-Rad Laboratories, Hercules, CA, USA) using 
ReadyMix™ Taq PCR Reaction Mix with MgCl2 (Sigma-
Aldrich), primer pairs designed to detect peptidylglycine 
α-amidating monooxygenase (PAM) and housekeeping gene 
GAPDH (Table II). PCR products were electrophoresed on 
2% agarose gel (Sigma-Aldrich) pre-stained with GelRed™, 
and then visualized by Uv transilluminator Gel Doc 2000 Gel 
Documentation system (Bio-Rad Laboratories).
ADM secretion assay. The constant release of endogenous 
ADM into culture medium was studied in HL60 cells using 
protein transport inhibition. Cells were seeded at density 
of 1x105 cells/ml and then cultured for 12, 36 and 60 h in 
proliferation medium before incubation for 12 h at 37˚C with 
GolgiPlug™ (BD Biosciences). At 24, 48 and 72 h after plating, 
the samples were collected and then submitted to permeabili-
zation with BD Cytofix/Cytoperm solution. The analysis was 
performed by intracellular ADM staining followed by flow 
cytometric analysis, as above reported. In the present study, 
cultures untreated with GolgiPlug™ were used as positive 
control of ADM secretion. The acquired data were analyzed 
by the overton substraction tool of Summit 4.3 software 
(Beckman Coulter, Inc., Brea, CA, USA) and were reported 
as percentage (%) ± SD of ADM positive cells compared with 
relative II Ab-matched control.
Treatment of HL60 cells with exogenous ADM and ADM22‑52. 
Cells were seeded in 25-cm2 flasks at a density of 1x105 cells/ml 
and then cultured for 72 h with different concentrations of 
ADM (ranging from 0.625x10-8 M to 5x10-8 M) (Sigma-
Aldrich) or 5x10-7 M ADM22-52 (Sigma-Aldrich) (13,18,20). In 
parallel, untreated cultures were used as reference. At the end 
of the treatment, growth assay and FCM analysis of endog-
enous ADM system were carried out. In parallel, cytospin 
preparations for May-Grunwald Giemsa staining were made 
to detect morphological changes of the nuclei.
Growth assay. At 72 h, cell suspensions were collected and 
then centrifuged at 1,200 rpm for 5 min at 4˚C. After resus-
pension of pellets in 1 ml of Iscove's medium, HL60 cells 
were counted by Nexcelom Bioscience-Auto T4 Cellometer 
(Invitrogen-Life Technologies). Data are expressed as mean 
of total cell number ± SD of three independent experiments 
performed in triplicate. Statistical analysis was performed 
using the Student's t-test.
Investigation of PI3K/Akt and MAPK/ERK signaling pathways. 
At different time-points (5, 15 and 30 min) after stimula-
tion, the activation of PI3K/Akt and MAPK/ERK signaling 
pathways was evaluated in HL60 cells treated with 5x10-8 M 
ADM and 5x10-7 M ADM22-52. The analysis was performed 
by FCM as previously described, using antibodies specific 
for phosphorylated and unphosphorylated forms of Akt and 
MAPK enzymes (Table I). In parallel, untreated samples were 
used as reference. For each marker and its corresponding II 
Ab-matched control, data were reported as geometric mean 
fluorescence intensity (MFI) ± SD. Statistical significance was 
calculated using the Student's t-test comparing primed cells 
with resting samples.
Differentiative response of HL60 cells to ADMexo and ADM22‑52
Quantitative real‑time polymerase chain reaction (qPCR). 
The quantitative analysis of Cullin 5 (Cul5) gene expres-
Table II. Primer sequences used for RT-PCR and qPCR analysis.
   Length
Target Sequence (5'-3') Accession (bp)
Peptidylglycine α-amidating monooxygenase (PAM) F-GCGCAAGCACTTTGATATGCCTCA
 R-TCTGCAATTCTGAGGAGGTGGGTT NM_000919.3 220
Cullin 5 (Cul5) F-GAACCAAAGACCCAGAGAGAAA NM_003478.3 81
 R-GTCCTCCTAAGTTCAGCATCAG
Glyceraldehydes 3-phosphate dehydrogenase (GAPDH) F-AGGTCGGAGTCAACGGATTTGGT
 R-ACAAAGTGGTCGTTGAGGGCAATG NM_002046.3 910
Hypoxanthine-guanine phosphoribosyltransferase (HPRT) F-ATGGACAGGACTGAACGTCTTGCT
 R-TGAGCACACAGAGGGCTACAATG NM_000194.2 79
F, forward; R, reverse.
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sion was performed using Platinum® SYBR® Green qPCR 
SuperMix-UDG (Invitrogen-Life Technologies) and oligo 
primers (Invitrogen-Life Technologies) designed for the 
detection of Cul5 and hypoxanthine-guanine phosphoribo-
syltransferase (HPRT) housekeeping gene (Table II). The 
amplification reactions were performed using a DNA Engine 
Opticon Real-Time Thermal Cycler (Bio-Rad Laboratories). 
The relative expression of Cul5 mRNA was determined using 
the ∆∆CT Livak method (21) and data were reported as fold 
increase calculated using the 2-∆∆CT ± SD equation. 
FCM. At 72 h after stimulation with ADMexo and ADM22-52, the 
samples were collected and then analysed by flow cytometry 
to measure the expression of myeloid differentiation markers 
and adhesion molecules (CD45, CD34, CD66b, CD11b, 
CD11c, CD14, CD31 and CD38). The samples were prepared 
as described above using antibodies listed in Table I. For each 
marker, data were expressed as the ratio of geometric MFI 
(rMFI) ± SD derived from primed cells and relative resting 
samples. Statistical significance was calculated using the 
Student's t-test.
Histochemistry. Air-dried slides of cells were prepared using a 
Cytospin 4 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
at 500 rpm for 5 min. The slides were fixed in methanol (Sigma-
Aldrich) for 5 min and then stained for 5 min in 50% (v/v) 
May-Grunwald stain (Merck Millipore, Billerica, MA, USA) 
followed by 15 min in 10% Giemsa stain (Merck Millipore). 
Both stain solutions were freshly made using Sorenson's phos-
phate buffer (133 mM, pH 6.6). After staining, the slides were 
washed and destained for 5 min in the phosphate buffer.
Results and Discussion
Immunophenotype of HL60 cells. Before priming with 
ADMexo and ADM22-52, the immunophenotype of HL60 
cells was explored by FCM evaluating the expression level 
Figure 1. Characterization by flow cytometry of HL60 cells. Data were 
expressed as mean fluorescence intensity (MFI) ± SD. White bars, isotype- 
or secondary (II) Ab-matched control; black bars, target marker-matched 
samples.
Figure 2. (A) The immunophenotypic analysis was performed by FCM to detect the expression of endogenous ADM (ADMendo), ADM receptors (RAMP1/2/3, 
CRLR) using specific primary antibodies and Alexa Fluor 488- and PE-conjugated secondary antibody. In parallel, secondary antibody-matched controls 
were used as reference. For each marker, the percentage (%) ± SD of positive cells (grey peak) was detected by the substraction statistical tool of Summit 4.3 
software using as reference II Ab-matched control (black peak). (B) Analysis by RT-PCR of PAM gene in HL60 cells cultured at basal conditions. In parallel, 
the expression of GAPDH housekeeping gene was considered. The amplification products were electrophoresed on 2% agarose gel and stained by GelRed™.
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of undifferentiated and differentiated state markers (Fig. 1). 
The myeloid phenotype was confirmed by the expression 
of CD33 while the presence of stem cell compartment was 
suggested by the absent expression of CD117/CKIT, Lin 1 and 
CD34 (22,23). Moreover, the undifferentiated state of cells was 
demonstrated by the negative or low fluorescence intensity of 
HLA-DR, CD45, CD11b, CD11c and CD66b (24-27). Among 
adhesion molecules expressed by acute myelogenous leukemia 
blasts, CD31 (28,29) and CD38 (30) are reported to play pivotal 
role in the interaction of tumor cells with microenviromental 
elements, i.e. CD31 on the surface of marrow endothelial cells 
(CD31/CD31 and CD38/CD31 interactions) and hyaluronate 
(CD38/hyaluronate interactions). In the present study, an 
excess of CD31 relative to CD38 was detected (CD31/CD38 
MFI ratio >1) suggesting that HL60 cells have a high potential 
of transendothelial migration (31-33). Similar expression level 
of CD31, CD33, CD38 in HL60 and APL cells was considered 
important to define a prospective correlation between in vitro 
and in vivo conditions.
HL60 cells express ADM and its receptors. As reported 
in Fig. 2A, HL60 cells were shown to express ADMendo 
(94.7±2.8%), RAMP2 (20.0±2.3%), RAMP3 (31.5±2.8%) and 
CRLR (14.3±1.8%). In contrast, RAMP1 was not detected. 
The gene expression of peptidylglycine α-amidating mono-
oxygenase (PAM), that is the enzyme producing α-amidated 
bioactive peptide from the inactive precursor (34), confirmed 
the potential of cells to synthesize the active form of ADM 
(Fig. 2B). Produced by peripheral blood mononuclear and poly-
morphonuclear cells, ADM is known to regulate cell growth 
or differentiation through an autocrine mode of action (15). 
As shown in Fig. 3, the release of ADM endogenously 
synthetized by HL60 cells was evaluated using Brefeldin A/
GolgiPlug™ kit, a protein transport inhibitor that is able to 
prevent the secretion process and to trap peptides into intra-
cellular compartments. The increased immunoreactivity for 
ADM in GolgiPlug™-treated samples (24 h, 77.4±8.3%; 48 h, 
50.5±8.3%; and 72 h, 68.5±7.3%) compared to untreated cells 
(24 h, 33.4±2.8%; 48 h, 32.3±4.8%; and 72 h, 59.0±6.1%) was 
interpreted as indicative of the cytoplasmic accumulation of 
ADMendo while the decreased fluorescent signal suggested that 
HL60 constitutively secrete ADM into culture medium after 
synthesis, as previously reported (15).
ADMexo enhances the proliferation of HL60 cells. It is known 
that ADM is produced not only by cancer cells but also by 
endothelial, macrophages, and mast cells of tumor microenvi-
ronment (35), where it contributes to cancer pathogenesis both 
directly stimulating cancer cell growth or indirectly inducing 
angiogenesis and reducing the effectiveness of the immune 
system.
Our data (Fig. 4) show that exogenous ADM exerted a 
strong proliferative effect on HL60 cells, as already observed 
in several cell types (36-39). Indeed, after a 72 h incubation 
period, significant increases in cell number were detected in 
cultures treated with ADMexo compared to resting cells. In 
particular, 5x10-8 M ADM was shown to be the most effective 
Figure 3. ADM secretion in HL60 cells was demonstrated using protein 
transport inhibition. Cells were cultured for 12, 36 and 60 h in prolifera-
tion medium before incubation for 12 h with Brefeldin A/GolgiPlug™. Thus, 
the samples were collected at 24, 48 and 72 h from plating and analyzed 
by intracellular ADM staining followed by flow cytometric analysis. In this 
analysis, cultures untreated with GolgiPlug™ were used as positive control of 
ADM secretion. The acquired data were expressed as a percentage (%) ± SD 
of ADM positive cells (grey filled peak) compared to II Ab-matched control 
(black profile).
Figure 4. Proliferative effect of exogenous ADM solutions (from 0.625x10-8 M 
to 5x10-8 M) and 5x10 -7 M ADM22-52 on HL60 cells cultured for 72 h. 
Untreated cultures (ADMendo) were used as reference. Bars are means ± SD 
(n=10). *P<0.05 using the Student's t-test. *P<0.05 vs. ADMendo reference 
group; ●P<0.05 and ▲P<0.05 vs. 5x10-8 M ADMexo.
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concentration. In contrast, ADM22-52 demonstrated not to affect 
the proliferation of HL60 cells, since total cell number in 
primed cultures was comparable to that of untreated samples. 
ADMexo and ADM22‑52 affect the ADM system. In the present 
study, we explored by FCM the modulation of adrenomedullin 
system (ADMendo and its receptors) in HL60 cells treated 
with exogenous 5x10-8 M ADM or 5x10-7 M ADM22-52. When 
HL60 cells were in vitro cultured with ADMexo (Fig. 5A) and 
ADM22-52 (Fig. 5B), a different expression profile of ADMendo 
was detected in comparison to resting samples. In particular, at 
24 h, a decreased immunoreactivity for ADM was observed in 
primed samples suggesting that, probably due to an increased 
level of intracellular Ca2+ (40), a major release of endogenous 
ADM was promoted. At 72 h, the secretion rate of ADM was 
negatively controlled by ADMexo (Fig. 5A) but not under treat-
ment with ADM22-52 (Fig. 5B). It is known that the expression 
of RAMP isoforms may change between physiological and 
pathological conditions (41), determining the degree of cell 
response to ADM. The cell sensitivity to ADM stimulation is 
defined both by a balanced expression of RAMPs and CRLR 
at cell membrane and their rapid rate of recycling. It is reported 
that RAMPs play pivotal roles in the transport of CRLR to 
plasma membrane (42). At physiological conditions, the most 
abundant isoform is RAMP2. Under pathological conditions, 
significant changes in RAMP expression levels are active 
under a concomitant increase in plasma ADM level (43). In 
the present study, the expression of AMR1 (CRLR/RAMP2), 
AMR2 (CRLR/RAMP3) and CGRP (CRLR/RAMP1) 
components was demonstrated to be altered following the 
treatment with exogenous ADM and ADM22-52. Indeed, at 24 h, 
ADMexo upregulated RAMP1, RAMP3 and CRLR (Fig. 5A) 
while ADM22-52 was effective in increasing the expression 
of RAMP3, but drastically reduced CRLR (Fig. 5B). In both 
primed groups, probably due to a receptor degradation after 
internalization (43), RAMP2 significantly decreased (Fig. 5), 
suggesting that ADMexo and ADM22-52 mediated their activity 
at early phase by AMR1. These data were in accordance with 
Figure 5. Expression of ADMendo, RAMP1, RAMP2, RAMP3 and CRLR in HL60 cells cultured for 24 and 72 h with 5x10-8 M ADMexo (A) or 5x10-7 M 
ADM22-52 (B) solubilized in growth medium. The positive expression of each marker was expressed as mean fluorescence intensity (MFI) ± SD. Grey peak, 
samples treated with ADMexo or ADM22-52; black profile, untreated samples. The profiles are representative of three independent experiments.
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the hypothesis that an excess of ADM in bone marrow matrix 
could increase the responsiveness of leukemia cells to ADM 
upregulating CRLR, RAMP1 and RAMP3 (44), while the 
inhibition of ADM signaling could raise the cell insensitivity 
to stimulation by a significant reduction of ADM receptor 
system. At 72 h, a correlation between the increased expres-
sion level of RAMP1/2 and the release of ADM was observed 
in resting samples suggesting that HL60 cells could combine 
the release of ADM with the exposure of ADM receptors at 
cell membrane to control their growth. Notably, the treatment 
of HL60 cells with exogenous ADM reduced the release of 
ADMendo and the expression of RAMP1 and RAMP2 while no 
change was induced by ADM22-52 compared to resting cells. 
The expression of RAMP3 and CRLR was drastically reduced 
at 72 h in all experimental groups. Unlike previously reported 
by Poyner et al (42), ADM22-52 exerted inhibitory activity of 
ADM signaling in leukemia cells through a negative regula-
tion of CRLR expression, either by an increased receptor 
internalization followed by degradation or a block of receptor 
transport to plasma membrane. 
AKT and MAPK signaling pathways were differently modu‑
lated by ADMexo and ADM22‑52. Pleiotropic effects of ADM 
are reported to be mediated through several intracellular 
signal transduction pathways (43). Using HL60 leukemia cells, 
we explored by FCM the modulation exerted by 5x10-8 M 
ADM and 5x10-7 M ADM22-52 on PI3K/Akt and ERK/MAPK 
signaling pathways, that are involved in several haemato-
poiesis malignancies, including AML (45-49). As shown in 
Fig. 6, the simultaneous detection of p(Ser473)-Akt1/2/3 and 
phospho(Thr202/Tyr204)-p44/42 MAPK in resting cells 
(ADMendo) suggested a constitutive activity of both pathways 
in HL60 cells. Hayashi and colleagues (50) reported that 
PI3K/Akt positively regulates the MAPK cascade, facilitating 
maximal ERK responses to physiological stimuli, whereas 
activated ERK, in turn, negatively controls the PI3K/Akt 
pathway. In the present study (Fig. 6), the phosphorylation 
level of Akt in ADMendo reached the maximum value at 5 to 
15 min and decreased at 30 min. In parallel, the upregulation 
in MAPK activity from 15 to 30 min could be indicative of a 
reciprocal regulation loop between Akt and MAPK. Notably, 
the stimulation of HL60 with ADMexo and ADM22-52 differently 
affected the activity of both pathways. Under stimulation with 
ADMexo, an increase in the expression level of p(Ser473)-Akt 
and phospho(Thr202/Tyr204)-p44/42 MAPK was observed 
at 5 min indicating that HL60 cells were responsive to exog-
enous ADM via the PI3K/Akt and ERK/MAPK cascade. In 
samples treated with ADMexo compared to ADMendo group, 
the activation level of MAPK unchanged from 5 to 15 min 
Figure 6. Changes in the activation state of Akt and MAPK upon treatment with 5x10-8 M ADMexo and 5x10-7 M ADM22-52. The samples were collected at 5, 15 
and 30 min from stimulation and analyzed by intracellular detection of phospho(Ser473)-Akt1/2/3 and phospho(Thr202/Tyr204)-p44/42 MAPK followed by 
flow cytometric analysis. In parallel, untreated cultures (ADMendo) were used as reference. Hatched bars, II Ab-matched control; white bars, untreated samples 
(ADMendo); grey bars, ADMexo-treated samples; black bars, ADM22-52-samples. Bars are means ± SD (n=3). *P<0.05 vs. relative value of ADMendo reference 
group; ▲P<0.05 and ▲▲P<0.01 vs. relative value detected at 5 min in each experimental group; ●P<0.05 and ●●P<0.01 vs. relative value detected at 15 min in 
each experimental group.
Figure 7. Quantitative RT-PCR analysis of Cul5 expression in HL60 cells 
treated with 5x10-7 M ADM22-52 or untreated (ADMendo) for 24 and 72 h. In 
parallel, the expression of HPRT housekeeping gene was evaluated. The 
relative expression of Cul5 mRNA was determined using the ∆∆CT method. 
Data are reported as the fold difference calculated from the equation 2-∆∆CT 
± SD. *P<0.05 and ***P<0.01 vs. ADMendo reference group.
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while a significant decrease in phosphorylated Akt expres-
sion was observed. In contrast, the stimulation with ADM22-52 
promoted the maximum activation of Akt at 5 to 30 min and 
a downregulation of MAPK activity at 30 min. Based on this 
evidence, we hypothesized that the activity of ADMexo was 
mainly mediated by the ERK/MAPK pathway while that of 
ADM22-52 was especially involved in PI3K/Akt signaling.
ADM22‑52 induces a strong differentiative induction on HL60 
cells
qPCR. To verify the differentiative induction after the inhi-
bition of ADM system, the expression of Cul5 was assessed 
by quantitative RT-PCR (Fig. 7). Cul5 belongs to the Cullins 
gene family, including 7 isoforms identified in mammalians. 
Cul5, Asb-2 (ankyrin repeat SOCS box 2), a RING finger 
protein (ROC/Rbx), and an adapter protein complex (elongin 
B/C) form an E3 ubiquitin ligase complex that, due to an E2 
ubiquitin-conjugating enzyme, leading to the degradation 
of target proteins by 26S proteasome (51). As component of 
this complex, Cul5 brings the enzyme the substrate recogni-
tion components (52). Furthermore, it seems to act as tumor 
suppressor in breast cancer (53) and its expression decreases in 
B-cell chronic lymphocytic leukemia (54). At 24 and 72 h after 
stimulation with ADM22-52, Cul5 mRNA increased 1.35- and 
4.18-fold, respectively, in primed cells vs. resting cultures. Our 
data were in agreement with the increase of Cul5 mRNA and 
protein detected by Baxter et al (19) during ATRA-mediated 
differentiation of HL60 cells.
FCM. Several reports highlighted that PI3K/Akt and 
ERK/MAPK signaling pathways control the self-renewal and 
differentiation of leukemia cells. Akt was demonstrated to exert 
its activity (55) activating nuclear factor-kappa B (NF-κB) (56), 
phosphorylating GSK-3 (57) and inhibiting transcription 
factors of FOXO family (58). Marcinkowska et al (59) demon-
strated that ERK/MAPK pathway stimulates the monocytic 
differentiation of HL60 cells through the phosphorylation 
of transcription factor C/EBPβ. As shown in Fig. 8A, the 
treatment with 5x10-8 M ADMexo was accompanied by an 
upregulation in the expression level of CD14 and CD31, which 
are associated with monocytic differentiation of HL60 cells 
(59,60). Interestingly, a decreased (rMFI<1) or unchanged 
(rMFI=1) expression level of other markers was observed in 
comparison to resting samples (ADMendo), suggesting that 
ADMexo could exert a negative control on the granulocytic 
differentiation process. In samples treated for 72 h with 
ADM22-52, FCM analysis evidenced a significant increase in the 
expression level of CD11b, a subunit of αMβ2 integrin, CD11c, 
an integrin αX, and CD66b, a granulocyte-specific activation 
antigen expressed on secondary granule membranes, that are 
all associated with granulocytic differentiation of HL60 cells 
(21,61,62). Moreover, we observed the upregulation of CD45 
Figure 8. (A) Expression of differentiation markers in HL60 cells stimulated with 5x10-8 M ADMexo or 5x10-7 M ADM22-52 for 72 h. The analysis was per-
formed by flow cytometry and data are reported as the ratio of geometric mean fluorescence intensity (rMFI) obtained for samples treated with ADMexo
 or 
ADM22-52 and untreated (ADMendo) cultures. White bars, ADMexo/ADMendo rMFI; black bars, ADM22-52/ADMendo rMFI. *P<0.05 and **P<0.01 vs. rMFI value≠1. 
(B) Morphological analysis by May Grunwald-Giemsa staining of untreated (ADMendo) and treated cells with ADMexo or ADM22-52. Low magnification, x400; 
high magnification, x1,000.
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and CD38, that are reported to increase during myeloid matu-
ration (63,64) and ATRA-induced granulocytic/monocytic 
differentiation (24,64). The increased MFI value of CD14 
in ADM22-52 compared to that of ADMendo-samples further 
confirmed the granulocytic/monocytic maturation of HL60 
cells (65). It is known that the expression of CD31 and CD38 
on leukemic cells could exert a balanced control between 
extramedullary dissemination and marrow retention of 
leukemic cells. As previously demonstrated in ATRA-induced 
HL60 differentiation (66), an excess of CD38 relative to CD31 
(CD31/CD38 MFI ratio<1) was detected in ADM22-52-treated 
cells, suggesting a higher retention of cells in bone marrow 
through the interaction with hyaluronate. In contrast, the 
excess of CD31 relative to CD38 (CD31/CD38 MFI ratio >1) 
in samples treated with ADMexo evidenced an increased ability 
of transendothelial migration. 
Histochemistry. To investigate HL60 cell differentiation, 
nuclear morphology of cells stained with May-Grunwald-
Giemsa was performed (Fig. 8B). In ADMexo-treated cells, only 
ovoid and intended nuclei were detected, whereas ADM22-52 
determined the appearance of differentiated cells character-
ized by several multilobulated segmented nuclei.
Conclusions
Understanding the aberrant expression of self-renewal pathways 
in myeloid malignancies is an emerging area of investigation 
for the development of novel treatment strategies. Extrinsic 
factors driven by bone marrow microenvironment are reported 
to regulate the growth of hematopoietic stem cells (67) within 
supportive osteoblastic and vascular niches (68). Among the 
soluble factors secreted in BM niches by stem cells (69) and 
stromal compartment (10), ADM synergizes with stem cell 
factor and Flt-3 (FMS-like tyrosine kinase-3) ligand to induce 
the proliferation of primitive human CD34+CD38-lin-cells and 
to promote the expansion of CD34+ progenitors in culture (70). 
The development of hematopoietic malignancies causes a 
remodeling of BM microenvironment followed by the altera-
tion of HSC function, leukemia survival, protection of cancer 
cells from apoptotic stimuli and development of drug-resistant 
phenotype (67,71). Hypoxic conditions in leukemia niche are 
demonstrated to support the progression of cancer and to 
upregulate ADM (72), thus, suggesting a correlation between 
the survival of leukemia cells and the increased release of 
ADM in tumor microenviroment (10). Consistent with the 
above evidence, and studies in several human tumor cell lines, 
including HL60 and chronic monocytic leukemia (U937) (73), 
our results suggest for ADM a regulatory role in the prolifera-
tion of APL by paracrine effects, as already demonstrated for 
ADM in modulating the activity of the hypothalamo-pituitary-
adrenal axis (74), the growth of cardiac and vascular smooth 
muscle cells (75), the hemodynamics of brain, lungs, and 
kidneys (76), physiological and pathological angiogenesis (12). 
Using the in vitro model of HL60 cells, we demonstrated that 
exogenously administered ADM preserves promyelocytic 
leukemia cells from differentiation as shown under ADM 
signaling inhibition with ADM22-52 by the detection of typical 
differentiation features such as multilobulated segmented 
nuclei, Cul5 expression and increased expression level of 
granulocytic and monocytic antigens. As the treatment with 
exogenous ADM significantly stimulated the growth of HL60 
cells, we speculated that paracrine ADM acts in APL niche 
supporting the survival of leukemia cells and promoting their 
transendothelial migration upregulating the cellular expres-
sion of CD31 (64). Based on the consideration that ADM22-52 
stimulates both the maturation and the retention in the bone 
marrow of leukemia cells through an increased expression 
of CD38, as previously demonstrated in HL60 and human 
primary APL cells treated with ATRA (64), our data provide 
strong evidence for the therapeutical potential that the inhibi-
tion of ADM signaling could have in the treatment of APL. 
A potentially important therapeutic effect of the blockade of 
ADM22-52-sensitive receptors has been already demonstrated 
for endotoxic shock (77) and expansion of keratinocytes, fibro-
blasts (78) and adrenal cortical cells (79).
Further studies will be necessary to verify ADM expres-
sion in bone marrow microenvironment and its involvement in 
the induction and progression of hematopoietic malignancy.
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